Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy

Michael J. Davis, Reason Wilken, Maxwell A Fung, Danielle Tartar

Research output: Contribution to journalArticle

Abstract

As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.

Original languageEnglish (US)
Article number13
JournalDermatology Online Journal
Volume24
Issue number4
StatePublished - Apr 1 2018

Fingerprint

Dermatitis
Skin
Thyroiditis
Bullous Pemphigoid
Colitis
Therapeutics
Immunotherapy
Hepatitis
Immune System
Neoplasms
Pneumonia

Keywords

  • Anti-PD- 1
  • Anti-PD-L 1
  • Checkpoint inhibitor
  • Cutaneous reactions
  • Immune related adverse events
  • Lichenoid dermatitis lichenoid toxicity

ASJC Scopus subject areas

  • Dermatology

Cite this

Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy. / Davis, Michael J.; Wilken, Reason; Fung, Maxwell A; Tartar, Danielle.

In: Dermatology Online Journal, Vol. 24, No. 4, 13, 01.04.2018.

Research output: Contribution to journalArticle

@article{481573576a0841ff8ef71a348a67e26b,
title = "Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy",
abstract = "As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.",
keywords = "Anti-PD- 1, Anti-PD-L 1, Checkpoint inhibitor, Cutaneous reactions, Immune related adverse events, Lichenoid dermatitis lichenoid toxicity",
author = "Davis, {Michael J.} and Reason Wilken and Fung, {Maxwell A} and Danielle Tartar",
year = "2018",
month = "4",
day = "1",
language = "English (US)",
volume = "24",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "4",

}

TY - JOUR

T1 - Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy

AU - Davis, Michael J.

AU - Wilken, Reason

AU - Fung, Maxwell A

AU - Tartar, Danielle

PY - 2018/4/1

Y1 - 2018/4/1

N2 - As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.

AB - As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.

KW - Anti-PD- 1

KW - Anti-PD-L 1

KW - Checkpoint inhibitor

KW - Cutaneous reactions

KW - Immune related adverse events

KW - Lichenoid dermatitis lichenoid toxicity

UR - http://www.scopus.com/inward/record.url?scp=85048733248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048733248&partnerID=8YFLogxK

M3 - Article

C2 - 29906009

AN - SCOPUS:85048733248

VL - 24

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 4

M1 - 13

ER -